Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

NCT00400153 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1480

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Atrovent Respimat (20 mcg)
DRUG: COMBIVENT MDI (36/206 mcg)
DRUG: Combivent Respimat (20 mcg/100 mcg)
DRUG: Placebo via corresponding inhaler for blinding purposes

Sponsor

Boehringer Ingelheim